Biostatistics Quiz: Conflicts Of Interest And Reporting Bias
20 questions · exam conditions
0:00
Conflicts Of Interest And Reporting BiasQuestion 1 of 20

Two research groups investigated the same research question using similar methodologies. Group A, funded by a government agency, reported no significant effect (p=0.24). Group B, funded by a company with commercial interest in positive results, reported a significant effect (p=0.04) in a study with 20% larger sample size. Both groups used appropriate randomization and blinding procedures.

Assuming both studies were methodologically sound, what factor most likely explains the discrepant findings between these two research groups?

Group B's larger sample size provided greater statistical power to detect the true treatment effect
Group A's government funding led to more conservative statistical analysis approaches and reporting
Group B's commercial funding likely influenced outcome selection, measurement, or analysis decisions
Random variation between studies accounts for the different p-values observed in these comparable trials
← Back to quizzes

Biostatistics Quiz

Biostatistics Quiz: Conflicts Of Interest And Reporting Bias

Practice Conflicts Of Interest And Reporting Bias in Biostatistics with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Conflicts Of Interest And Reporting Bias, giving you a quick way to practice the rules, question types, and explanations that matter most for Biostatistics.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

Two research groups investigated the same research question using similar methodologies. Group A, funded by a government agency, reported no significant effect (p=0.24). Group B, funded by a company with commercial interest in positive results, reported a significant effect (p=0.04) in a study with 20% larger sample size. Both groups used appropriate randomization and blinding procedures.

Assuming both studies were methodologically sound, what factor most likely explains the discrepant findings between these two research groups?

  1. Group B's larger sample size provided greater statistical power to detect the true treatment effect
  2. Group A's government funding led to more conservative statistical analysis approaches and reporting
  3. Group B's commercial funding likely influenced outcome selection, measurement, or analysis decisions (correct answer)
  4. Random variation between studies accounts for the different p-values observed in these comparable trials
Explanation: Given the commercial interest in positive results, Group B's funding source most likely influenced subtle decisions about outcome selection, measurement timing, subgroup analyses, or statistical approaches (C). While larger sample size (A) could contribute, a 20% increase typically wouldn't shift results from p=0.24 to p=0.04. Government funding doesn't inherently create conservative bias (B), and random variation (D) is less likely to explain such systematic differences between funding sources.

Question 2

A systematic review examining the effectiveness of a medical device included 25 studies. The review authors noted that studies funded by the device manufacturer (n=15) reported effect sizes averaging 0.8 (95% CI: 0.6-1.0), while independently funded studies (n=10) reported effect sizes averaging 0.3 (95% CI: 0.1-0.5). All included studies met pre-specified methodological quality criteria.

Given that both groups of studies met quality standards, what is the most likely explanation for the systematic difference in reported effect sizes?

  1. Subtle biases in study design, conduct, or analysis influenced industry-funded studies toward more favorable results (correct answer)
  2. Independent funding sources imposed more stringent statistical analysis requirements leading to conservative effect estimates
  3. Industry-funded studies had larger sample sizes providing more precise estimates of the true treatment effect
  4. The device manufacturer selected study populations with characteristics more likely to respond to the intervention
Explanation: When you encounter questions about systematic differences in research outcomes based on funding source, you're dealing with research bias and conflict of interest issues—key concepts in evidence-based medicine and meta-analysis interpretation. The striking difference in effect sizes (0.8 vs 0.3) between industry-funded and independently-funded studies, despite both meeting quality criteria, points to subtle but systematic bias. Answer A correctly identifies that industry funding can introduce unconscious biases throughout the research process—from how endpoints are defined and measured, to which analyses are emphasized in reporting, to decisions about study duration or population selection. These biases can occur even in methodologically sound studies and are well-documented in medical literature. Answer B is incorrect because independent funders don't typically impose more stringent statistical requirements—if anything, they often have fewer restrictions on analysis approaches. Answer C misses the mark because larger sample sizes would increase precision (narrower confidence intervals), not necessarily inflate effect sizes. The confidence intervals shown don't suggest the industry studies had dramatically larger samples. Answer D assumes manufacturer studies used different populations, but this would typically be noted as a limitation in study selection criteria rather than appearing as a systematic pattern across multiple studies meeting the same inclusion standards. Study tip: When reviewing systematic reviews or meta-analyses, always examine funding sources and look for patterns in results based on who sponsored the research. This type of funding bias is a classic exam topic because it's so prevalent in real-world evidence evaluation.

Question 3

A pharmaceutical company funds a clinical trial of their new cholesterol medication. The study protocol requires reporting all adverse events, but the company's internal emails reveal they discussed ways to minimize reporting of mild gastrointestinal side effects in the final publication. Which type of bias is most directly illustrated by this scenario?

  1. Selection bias in participant recruitment for the study
  2. Reporting bias due to selective presentation of outcomes (correct answer)
  3. Recall bias from participants' memory of side effects
  4. Observer bias from unblinded outcome assessment
  5. Publication bias from journal preferences for positive results
Explanation: When you encounter questions about bias in clinical research, focus on identifying what specific aspect of the study design or conduct is being compromised. This scenario illustrates a clear case of selective information presentation after data collection is complete. The company's internal discussions about minimizing the reporting of mild gastrointestinal side effects represents reporting bias (answer B). This occurs when researchers selectively present, emphasize, or suppress certain findings in their publications. Even though the study protocol required reporting all adverse events, the company planned to downplay specific negative outcomes in their final publication. This creates a distorted picture of the medication's true safety profile for readers and future prescribers. Let's examine why the other options don't fit: Answer A (selection bias) involves problems with how participants are chosen for the study, not how results are reported afterward. Answer C (recall bias) refers to participants' inability to accurately remember past events or exposures, which isn't relevant since this involves the company's reporting decisions, not participant memory. Answer D (observer bias) occurs when researchers' expectations influence how they measure or assess outcomes during the study, but here the bias happens at the publication stage, not during data collection. Study tip: Remember that reporting bias occurs after data collection and involves selective presentation of results. Look for keywords like "discussed ways to minimize," "chose not to publish," or "emphasized positive findings" to identify this type of bias on exam questions.

Question 4

A meta-analysis of antidepressant effectiveness shows strong positive results. However, the authors only included published studies and excluded unpublished trials with negative results that were registered in clinical trial databases. This limitation most directly represents:

  1. Reporting bias within individual studies included in the meta-analysis
  2. Selection bias in choosing which patient populations to study
  3. Publication bias affecting the overall evidence base being analyzed (correct answer)
  4. Observer bias in how outcomes were measured across studies
  5. Recall bias from retrospective data collection methods used
Explanation: When you encounter questions about systematic reviews and meta-analyses, focus on identifying different types of bias that can affect the validity of the pooled evidence. The key distinction is whether the bias occurs within individual studies or in how studies are selected for inclusion. This scenario describes a classic case of publication bias. The meta-analysis authors systematically excluded unpublished negative trials that were registered in databases, meaning they only analyzed studies that made it to publication. This creates a skewed evidence base because negative results are less likely to be published, leading to an overly optimistic pooled effect estimate. Publication bias affects which studies enter the literature and become available for systematic review. Option A is incorrect because reporting bias occurs within individual studies when authors selectively report favorable outcomes while suppressing unfavorable ones. Here, the bias isn't happening within each included study, but rather in which studies get included. Option B misses the mark because selection bias in patient populations would involve choosing non-representative study participants. The issue here isn't about who was studied, but about which completed studies were analyzed. Option D is wrong because observer bias involves systematic errors in how outcomes are measured or assessed. The measurement methods aren't the problem—the problem is the systematic exclusion of negative studies from the analysis. Remember: Publication bias is a major threat to meta-analyses. Always check whether authors searched for unpublished studies, conference abstracts, and trial registries. The phrase "file drawer problem" refers to this same concept.

Question 5

An investigator studying dietary supplements has received consulting fees from three different supplement manufacturers over the past two years. When submitting a manuscript about supplement safety, which disclosure approach best addresses potential conflicts of interest?

  1. No disclosure needed since the current study wasn't directly funded by these companies
  2. Disclose only relationships with companies whose products were specifically studied
  3. Disclose all financial relationships with supplement companies regardless of study focus (correct answer)
  4. Disclosure is only required if the relationships influenced the study conclusions
  5. Disclose only relationships that exceeded a specific monetary threshold
Explanation: When you encounter questions about conflicts of interest in research, think about the fundamental principle: transparency protects scientific integrity and public trust. The goal isn't just to avoid actual bias, but to allow readers to identify any potential sources of bias. The correct approach is to disclose all financial relationships with supplement companies regardless of study focus (C). This comprehensive disclosure standard exists because conflicts of interest can be subtle and far-reaching. Even if a researcher studied Company A's products but received consulting fees from Companies B and C, those relationships could still influence how they frame questions, interpret data, or draw conclusions about the supplement industry broadly. Readers deserve to know about all potential conflicts so they can evaluate the research appropriately. Option A is wrong because funding source isn't the only relevant financial relationship—consulting fees, speaking honoraria, and other payments can all create conflicts. Option B fails because limiting disclosure to only the specific products studied ignores how industry relationships can create broader biases toward favorable interpretations of supplement research generally. Option D incorrectly suggests that disclosure depends on whether conflicts actually influenced conclusions, but researchers often can't objectively assess their own bias, and the appearance of conflict matters as much as actual influence. Study tip: Remember that conflict of interest disclosure follows a "when in doubt, disclose" principle. On biostatistics exams, questions about research ethics typically favor the most transparent, comprehensive approach to maintaining scientific integrity.

Question 6

A clinical trial protocol specifies five primary endpoints, but the published paper emphasizes only the two endpoints that showed statistically significant results, while briefly mentioning the three non-significant endpoints in a table. This practice primarily represents:

  1. Appropriate focus on clinically meaningful findings from the study
  2. Selective reporting bias that misrepresents the study's overall results (correct answer)
  3. Standard practice for highlighting the most important study outcomes
  4. Necessary brevity due to journal word limits and space constraints
  5. Proper emphasis of statistically significant findings over null results
Explanation: When you encounter questions about research reporting practices, focus on the fundamental principle that scientific integrity requires transparent presentation of all pre-specified outcomes, regardless of their statistical significance. This scenario describes selective reporting bias (also called outcome reporting bias), where researchers emphasize favorable results while downplaying unfavorable ones. The protocol specified five primary endpoints — these are the main outcomes the study was designed and powered to detect. By highlighting only the two significant results while burying the three non-significant ones in a table, the authors misrepresent their study's overall findings and violate scientific reporting standards. Option A is incorrect because clinically meaningful findings should include both positive and negative results — knowing what doesn't work is often as valuable as knowing what does. Option C mischaracterizes this as standard practice, when in fact it represents poor scientific conduct that journals and regulatory agencies actively discourage. Option D incorrectly suggests space constraints justify selective emphasis of pre-specified primary endpoints; primary outcomes should receive equal prominence regardless of their significance. This selective presentation can mislead readers about treatment effectiveness and contribute to publication bias in systematic reviews and meta-analyses. The appropriate approach would be to present all five primary endpoints with equal emphasis, discussing the clinical implications of both significant and non-significant findings. Study tip: Remember that pre-specified primary endpoints must be reported transparently regardless of significance. When you see questions about emphasizing only positive results while downplaying negative ones, think "selective reporting bias."

Question 7

A systematic review finds that 15 published studies show positive effects of a new therapy, while 3 show no effect. However, a search of trial registries reveals 8 additional completed but unpublished studies. If these unpublished studies were more likely to have negative results, what bias does this scenario best illustrate?

  1. Selection bias in the choice of study participants across trials
  2. Information bias due to poor outcome measurement in studies
  3. Publication bias creating an incomplete evidence base for review (correct answer)
  4. Reporting bias within the individual published studies analyzed
  5. Confounding bias from unmeasured variables across study populations
Explanation: When you encounter questions about biases in systematic reviews or meta-analyses, focus on distinguishing between biases that occur within individual studies versus those that affect which studies make it into the review itself. This scenario describes publication bias, where studies with positive or statistically significant results are more likely to be published than those with negative or null findings. The key evidence here is that 8 completed studies remain unpublished and are suspected to have negative results. This creates a skewed evidence base where the systematic review only captures the "successful" studies, making the therapy appear more effective than it actually is. Option A is incorrect because selection bias refers to how participants are chosen within individual studies, not which studies get published. The bias here isn't about who was enrolled in the trials, but about which completed trials became available for review. Option B addresses information bias, which involves measurement errors or misclassification within studies. The problem isn't that outcomes were measured poorly—it's that entire studies with certain types of results are missing from the published literature. Option D describes reporting bias, where researchers selectively report only favorable outcomes from within their studies while omitting negative findings from the same study. Here, the issue is that entire studies are missing, not selective reporting within published studies. Remember this pattern: when you see "unpublished studies" or "studies sitting in file drawers" combined with suspicion that these missing studies have different results than published ones, think publication bias immediately.

Question 8

An epidemiologist receives a research grant from an environmental advocacy organization to study air pollution health effects. The organization's mission is to demonstrate environmental health harms. When reporting this funding source, what additional step would best address potential conflicts of interest?

  1. Return the funding to avoid any appearance of conflict of interest
  2. Acknowledge the funder's advocacy mission and describe steps taken to ensure objectivity (correct answer)
  3. Only disclose the funding amount without mentioning the organization's mission
  4. Delay publication until funding from a neutral source can be obtained
  5. Have the advocacy organization review the manuscript before submission
Explanation: When you encounter questions about conflicts of interest in research, focus on the principle of transparency with mitigation rather than avoidance at all costs. Research funding often comes from organizations with specific interests, and the goal is to maintain scientific integrity while acknowledging potential biases. The best approach is to acknowledge the funder's advocacy mission and describe steps taken to ensure objectivity (B). This demonstrates transparency by fully disclosing not just who provided funding, but their potential motivations. More importantly, it shows that the researcher has actively considered how bias might influence the study and has implemented safeguards like independent data analysis, peer review, or predetermined protocols to maintain objectivity. Option A (returning the funding) is unnecessarily extreme and would severely limit research funding sources, as many organizations have some advocacy component. Option C (disclosing only the amount) fails to provide readers with crucial information about potential bias sources - the funder's mission is often more relevant than the dollar amount. Option D (delaying publication) is impractical since truly "neutral" funding sources are rare, and this would unnecessarily delay important research from reaching the public. The key principle here is that conflicts of interest aren't automatically disqualifying - they need to be managed and disclosed transparently. Readers can then evaluate the research with full knowledge of potential biases. Study tip: Remember that in biostatistics and research ethics, transparency plus mitigation typically beats avoidance. Look for answers that acknowledge potential problems while describing concrete steps to address them.

Question 9

A clinical trial of a diabetes medication measures 12 different metabolic parameters. The study protocol designated HbA1c as the primary endpoint, but the published paper leads with impressive results for weight loss (a secondary endpoint) while relegating the modest HbA1c improvement to later in the results section. This represents:

  1. Appropriate emphasis on the most clinically relevant patient outcome
  2. Selective outcome reporting that misrepresents study priorities (correct answer)
  3. Standard practice for presenting multiple endpoints in clinical trials
  4. Necessary reorganization to highlight statistically significant findings
  5. Proper focus on unexpected beneficial effects discovered in the trial
Explanation: When you encounter questions about clinical trial reporting, focus on the fundamental principle that studies should present results according to their pre-specified design and stated objectives, not based on which results look most impressive. This scenario describes a classic case of selective outcome reporting bias. The researchers designated HbA1c as the primary endpoint in their protocol, meaning this was the main outcome they intended to measure and the basis for their sample size calculations and statistical power. By burying the modest HbA1c results while prominently featuring the impressive weight loss results (a secondary endpoint), they're misrepresenting their study's actual priorities and potentially misleading readers about what the trial was designed to demonstrate. Choice A is wrong because clinical relevance doesn't justify reorganizing results contrary to the pre-specified analysis plan. Choice C misunderstands standard practice—proper reporting presents primary endpoints first, regardless of their statistical significance or clinical drama. Choice D reveals a dangerous misconception: statistical significance should never dictate how you reorganize your pre-planned analysis hierarchy, as this introduces bias and undermines the scientific method. This type of selective reporting can make ineffective treatments appear successful by cherry-picking favorable secondary outcomes while downplaying disappointing primary results. It's a form of research misconduct that regulatory agencies and journal editors actively work to prevent. Study tip: On biostatistics exams, remember that research integrity trumps impressive results. Any deviation from pre-specified protocols—whether in analysis, reporting, or emphasis—should raise red flags about potential bias, regardless of how "positive" the highlighted results appear.

Question 10

A researcher has published several papers critical of a particular medical device. The researcher is now invited to serve on an FDA advisory panel reviewing the safety of that same device. What is the most appropriate approach to this potential conflict?

  1. Decline to serve since prior publications create an insurmountable bias
  2. Serve on the panel but recuse from discussions about the specific device
  3. Disclose prior publications and let the FDA decide on participation (correct answer)
  4. Serve without disclosure since published opinions are part of scientific expertise
  5. Agree to serve only if allowed to modify previous published positions
Explanation: Questions about conflicts of interest in research and regulatory settings test your understanding of research ethics and transparency principles. The key is balancing the value of expertise with the need for ethical oversight. The most appropriate approach is to disclose prior publications and let the FDA decide on participation (C). This follows the fundamental principle of transparency in research ethics. The researcher has valuable expertise that could benefit the review process, but also has a potential conflict that needs to be evaluated. By disclosing their prior critical publications, they provide the FDA with complete information to make an informed decision about whether their participation is appropriate and how to manage any potential bias. Option A is too restrictive - prior publications don't automatically disqualify someone from serving, especially since critical evaluation is part of scientific expertise. The FDA may still want this person's knowledge while implementing safeguards. Option B creates a problematic situation where the panel member would be present but silent on the main topic, wasting their expertise while potentially still influencing discussions indirectly. Option D is ethically problematic because it withholds relevant information that could affect the panel's objectivity and public trust in the process. When you encounter research ethics questions, remember that transparency and disclosure are almost always preferred over either complete avoidance or non-disclosure. The goal is to harness expertise while maintaining public trust and scientific integrity through proper oversight and informed decision-making by the appropriate authorities.

Question 11

A pharmaceutical company sponsors a clinical trial but contractually requires that all publications must be approved by the company before submission. The investigators agree to this arrangement. This contract provision most directly threatens:

  1. The validity of the study's statistical analysis methods
  2. The reliability of the study's outcome measurements
  3. The independence of scientific reporting and interpretation (correct answer)
  4. The adequacy of the study's sample size calculations
  5. The appropriateness of the study's inclusion criteria
Explanation: When you encounter questions about research ethics and contractual arrangements in clinical trials, focus on how external pressures might compromise the scientific process. The key issue here is identifying which aspect of research integrity is most directly at risk. The requirement for company approval before publication creates a fundamental conflict between scientific objectivity and commercial interests. This arrangement directly threatens the independence of scientific reporting and interpretation (C) because it gives the sponsor veto power over how results are presented, analyzed, and discussed. Researchers might feel pressured to downplay negative findings, emphasize positive results, or modify their interpretation to align with the company's commercial interests. This compromises the core principle that scientific conclusions should be based solely on data and evidence, not influenced by financial stakeholders. Option A is incorrect because the statistical analysis methods themselves aren't necessarily compromised—the study can still use appropriate statistical techniques. The threat is to how those results are reported, not how they're calculated. Option B misses the mark because the reliability of outcome measurements isn't affected by publication approval requirements—the data collection process remains intact. Option D is wrong because sample size calculations are typically determined during study design, well before any publication approval issues arise. Remember that research ethics questions often test your ability to distinguish between threats to data integrity (how studies are conducted) versus threats to scientific integrity (how results are reported and interpreted). Publication control arrangements always raise red flags about scientific independence, even when the underlying research methodology remains sound.

Question 12

An investigator studying cancer treatment effectiveness has received speaking honoraria from five different pharmaceutical companies over the past three years. When submitting a manuscript about cancer therapy, the investigator lists only the two companies whose drugs were mentioned in the current study. This disclosure approach is:

  1. Appropriate since only directly relevant relationships need disclosure
  2. Inadequate because all pharmaceutical relationships could influence cancer research (correct answer)
  3. Excessive since speaking fees don't create meaningful conflicts of interest
  4. Correct since only research funding requires disclosure, not speaking fees
  5. Sufficient if the undisclosed relationships were below monetary thresholds
Explanation: When evaluating conflicts of interest in biomedical research, you need to understand that disclosure requirements are deliberately broad because potential influences can be subtle and far-reaching. The key principle is that any financial relationship that could reasonably be perceived as creating bias should be disclosed, regardless of whether it directly relates to the specific study. Option B is correct because all pharmaceutical relationships could potentially influence how an investigator approaches, designs, or interprets cancer research. Even if the investigator received speaking fees from companies whose drugs aren't mentioned in the current study, those relationships could still create unconscious biases about treatment approaches, competitor products, or research priorities. The "appearance of impropriety" standard requires disclosure of all relevant relationships within a specified timeframe (typically 3-5 years). Option A incorrectly assumes that only direct relationships matter, missing the broader principle that any pharmaceutical relationship could influence cancer research perspectives. Option C underestimates the significance of speaking honoraria—these payments can create meaningful financial relationships and loyalty to specific companies. Option D misunderstands disclosure requirements entirely; speaking fees, consulting arrangements, and research funding all require disclosure, not just research funding. Study tip: Remember that conflict of interest disclosure follows the "when in doubt, disclose it" principle. On biostatistics exams, questions about research ethics typically test whether you understand that disclosure requirements are intentionally comprehensive to maintain public trust in research, even if some relationships seem tangentially related.

Question 13

A meta-analysis of antihypertensive drug effectiveness shows that industry-sponsored trials report larger effect sizes than government-funded trials studying the same medications. Assuming similar study quality, this pattern most likely reflects:

  1. Better patient compliance in industry-sponsored trials
  2. More rigorous inclusion criteria in government studies
  3. Reporting bias favoring sponsors' interests in industry trials (correct answer)
  4. Superior study design expertise in industry-sponsored research
  5. Different patient populations between industry and government studies
Explanation: When you encounter questions about systematic differences in research outcomes based on funding sources, you're dealing with research bias and conflicts of interest - a crucial area in biostatistics and evidence-based medicine. The key insight here is that when studies of similar quality consistently show different results based on who funded them, methodological factors are less likely explanations than bias. Industry-sponsored trials showing consistently larger effect sizes for the sponsor's products suggests reporting bias - the selective presentation of results that favor the sponsor's commercial interests. This can manifest through selective outcome reporting, favorable data interpretation, or publication of only positive results while suppressing negative ones. Looking at the incorrect options: Option A (better patient compliance) would be a methodological difference, but the question states study quality is similar, making this unlikely to systematically favor industry trials. Option B (more rigorous inclusion criteria in government studies) might explain smaller effect sizes in government trials, but again, similar study quality makes this less plausible as a systematic explanation. Option D (superior study design expertise) contradicts the premise of similar study quality and doesn't explain why expertise would systematically favor the sponsor's interests rather than simply producing more accurate results. The correct answer is C because reporting bias provides the most logical explanation for systematic differences favoring sponsors across similar-quality studies. Study tip: When you see systematic outcome differences based on funding source despite similar methodology, always consider financial conflicts of interest and reporting bias before methodological explanations. This pattern appears frequently in biostatistics questions about research integrity.

Question 14

A researcher discovers that a dietary supplement they have been studying for five years causes significant liver toxicity. The researcher owns stock in the company that manufactures this supplement. What is the most appropriate action?

  1. Delay publication until the stock position can be divested
  2. Publish immediately with full disclosure of the financial conflict (correct answer)
  3. Seek additional funding to replicate the findings before publishing
  4. Transfer authorship to a colleague without financial conflicts
  5. Publish without disclosure since the findings are negative for the company
Explanation: When you encounter questions about research ethics and conflicts of interest, the key principle is that scientific integrity and public safety must take precedence over personal financial interests, while maintaining transparency about potential biases. The most appropriate action is to publish immediately with full disclosure of the financial conflict (B). When research reveals serious safety concerns like liver toxicity, the ethical imperative is to share this critical information with the scientific community and public as quickly as possible to prevent harm. The researcher's financial conflict doesn't invalidate the findings, but it must be transparently disclosed so readers can evaluate the research with full knowledge of potential bias. This approach balances scientific integrity with ethical transparency. Option A is problematic because delaying publication to divest stock puts financial interests before public safety—people could continue suffering liver damage while the researcher manages their portfolio. Option C seeks unnecessary replication that would delay sharing crucial safety information; while replication is valuable, it shouldn't postpone publication of findings about serious adverse effects. Option D inappropriately attempts to hide the conflict of interest by transferring authorship, which is deceptive since the original researcher conducted the work and has the financial stake. Remember this principle for biostatistics ethics questions: when research reveals safety concerns, immediate transparent disclosure always trumps protecting financial interests or avoiding uncomfortable conflicts. The scientific community relies on honest reporting of both findings and potential biases to make informed decisions about public health.

Question 15

A systematic review of vaccine safety includes 20 published studies showing vaccines are safe, but excludes 5 unpublished studies with similar methodology that found no safety concerns. The review authors excluded the unpublished studies because they "lack peer review." This decision most likely introduces:

  1. Selection bias by excluding methodologically sound evidence
  2. Information bias due to poor quality control measures
  3. Publication bias by preferring published over unpublished work (correct answer)
  4. Reporting bias within the included published studies
  5. Observer bias in how safety outcomes were assessed
Explanation: When evaluating systematic reviews and meta-analyses, you need to recognize different types of bias that can compromise the validity of findings. This question tests your ability to distinguish between various forms of bias based on how studies are selected and included. The scenario describes authors excluding unpublished studies solely because they "lack peer review," despite having similar methodology and findings. This represents publication bias – the systematic tendency to preferentially include published studies over unpublished ones. Publication bias occurs when study selection is based on publication status rather than methodological quality, potentially skewing results since published studies may differ systematically from unpublished ones. Let's examine why the other options don't fit: Option A (Selection bias) is too broad and doesn't capture the specific mechanism at work. While technically a form of selection bias, the more precise term for bias based on publication status is publication bias. Option B (Information bias) refers to systematic errors in data collection or measurement within studies, not in study selection for a review. Option D (Reporting bias) occurs within individual studies when authors selectively report certain outcomes or analyses, not when review authors exclude entire studies based on publication status. Study tip: Remember that publication bias specifically refers to the preferential inclusion of published over unpublished work in systematic reviews. When you see questions about excluding studies based on publication status rather than methodological quality, publication bias should be your first consideration. This is a critical concept in evidence-based medicine and meta-analysis.

Question 16

A clinical trial protocol lists "cardiovascular events" as the primary endpoint, but the published paper focuses on "cardiovascular mortality" (a subset of the original endpoint) because the broader endpoint was not statistically significant. The mortality endpoint was significant. This change represents:

  1. Appropriate refinement of endpoints based on clinical relevance
  2. Standard practice for focusing on the most meaningful outcomes
  3. Selective outcome reporting that changes pre-specified endpoints (correct answer)
  4. Necessary adjustment due to unexpected event patterns in the trial
  5. Proper emphasis on hard endpoints over composite measures
Explanation: When you encounter questions about changes between trial protocols and published results, you're being tested on research integrity and selective outcome reporting - a critical issue in evidence-based medicine. This scenario describes a classic case of selective outcome reporting bias. The researchers pre-specified "cardiovascular events" as their primary endpoint in the protocol, but when this broader measure didn't reach statistical significance, they shifted focus to the narrower "cardiovascular mortality" subset that did show significance. This practice undermines the validity of statistical inference because it increases the chance of finding spurious significant results through multiple testing. Option C correctly identifies this as selective outcome reporting that changes pre-specified endpoints. The key red flag here is that the change was driven by statistical results rather than scientific rationale. Option A is wrong because appropriate endpoint refinement should be based on clinical considerations established before seeing results, not statistical outcomes. Option B incorrectly suggests this is standard practice - while focusing on meaningful outcomes is important, changing endpoints post-hoc based on significance is considered poor methodology. Option D is incorrect because the scenario provides no evidence of "unexpected event patterns" - the change appears motivated solely by achieving statistical significance. Remember this pattern: When protocols and publications differ regarding endpoints, especially when changes favor significant results, suspect selective reporting bias. This is a major threat to research validity that regulatory agencies and journals actively combat through trial registration requirements.

Question 17

A researcher analyzing clinical trial data discovers that including all randomized patients shows no significant treatment benefit, but excluding patients who discontinued treatment early shows significant benefit. The published paper presents only the analysis excluding early discontinuations. This approach most directly represents:

  1. Appropriate per-protocol analysis for regulatory submissions
  2. Standard practice for handling treatment discontinuations
  3. Selective analysis reporting based on statistical significance (correct answer)
  4. Necessary adjustment for non-adherent study participants
  5. Proper focus on patients who completed the intended treatment
Explanation: When you encounter questions about research reporting practices, focus on the ethical principles of transparency and avoiding bias in how results are presented. This scenario describes a classic case of selective reporting based on statistical significance. The researcher conducted two analyses: an intention-to-treat (ITT) analysis including all randomized patients (showing no benefit) and a per-protocol analysis excluding early discontinuations (showing benefit). Publishing only the favorable result while omitting the unfavorable one constitutes selective reporting, which can mislead readers about the true treatment effect. Choice C correctly identifies this as selective analysis reporting based on statistical significance. The researcher cherry-picked results that supported their hypothesis while suppressing contradictory findings. Choice A is incorrect because while per-protocol analyses can be appropriate for regulatory submissions, they should be presented alongside ITT analyses, not as replacements. Presenting only favorable results isn't appropriate regardless of the submission type. Choice B is wrong because standard practice requires reporting both ITT and per-protocol analyses when both are conducted. Transparency demands showing all planned analyses, especially when results differ substantially. Choice D mischaracterizes the situation as a necessary adjustment. While excluding non-adherent participants can provide valuable insights, doing so selectively based on whether results reach significance represents bias, not scientific necessity. Remember this key principle: legitimate research requires transparent reporting of all conducted analyses, especially when results conflict. Watch for scenarios where researchers present only favorable findings while hiding unfavorable ones—this always signals selective reporting bias.

Question 18

A university researcher collaborates with a biotechnology company on a joint research project. The company provides funding and laboratory facilities, while the university provides scientific expertise. When publishing results, what disclosure approach best addresses potential conflicts?

  1. Disclose only the direct financial support received from the company
  2. No disclosure needed since this is a legitimate academic-industry collaboration
  3. Disclose the collaboration, funding, and any individual financial relationships (correct answer)
  4. Disclose only if the results favor the company's commercial interests
  5. List the company as a co-author instead of disclosing conflicts
Explanation: When evaluating research conflicts of interest, transparency is the cornerstone of ethical scientific practice. Academic-industry collaborations create complex relationship webs that can influence research design, data interpretation, and publication decisions, even when researchers maintain the highest integrity. The correct approach requires comprehensive disclosure of all relevant relationships. Option C correctly captures this principle by requiring disclosure of the collaboration itself, the funding arrangements, and any individual financial relationships between researchers and the company. This complete transparency allows readers, reviewers, and the scientific community to evaluate potential biases and interpret results appropriately. Option A fails because limiting disclosure to direct financial support ignores other influential factors like facility access, equipment provision, or future collaboration prospects that could unconsciously shape research decisions. Option B represents a dangerous misconception—legitimacy doesn't eliminate conflict of interest. Even ethically sound collaborations create potential conflicts that must be disclosed. Option D is particularly problematic because it suggests selective disclosure based on results, which undermines scientific integrity. Conflicts exist regardless of whether findings favor the sponsor, and determining what "favors" a company can be subjective and complex. Remember this key principle for biostatistics ethics questions: when in doubt, err on the side of over-disclosure rather than under-disclosure. The goal isn't to avoid all industry collaborations—they're often valuable—but to maintain transparency so the scientific community can properly evaluate the research within its full context.

Question 19

A meta-analysis examining the effectiveness of a new surgical procedure finds that studies published in high-impact journals show larger effect sizes than studies published in specialty journals, despite similar methodological quality. This pattern most likely suggests:

  1. Superior peer review processes in high-impact journals
  2. Better surgical technique in studies submitted to prestigious journals
  3. Publication bias favoring dramatic results in high-impact venues (correct answer)
  4. More rigorous statistical analysis in high-impact journal submissions
  5. Different patient populations studied by high-impact journal authors
Explanation: When you encounter questions about patterns in research findings across different publication venues, think about the various biases that can affect what gets published and where. The scenario describes studies of similar methodological quality showing different effect sizes based solely on journal prestige. This pattern strongly indicates publication bias - the tendency for journals, especially high-impact ones, to preferentially publish studies with dramatic, statistically significant, or novel results. High-impact journals often seek studies that will generate citations and attention, creating pressure to publish research with larger effect sizes even when methodology is comparable across venues. Option A is incorrect because superior peer review would actually lead to more consistent, not inflated, effect sizes across studies of similar quality. Better peer review typically reduces bias rather than creating systematic differences in reported effects. Option B assumes surgical technique varies by submission venue, but there's no logical reason why researchers using better techniques would systematically choose high-impact journals over specialty journals, especially since specialty journals often have more relevant expert reviewers. Option D suggests statistical analysis quality differs by journal type, but the question states methodological quality is similar across venues. More rigorous statistics would likely reduce effect sizes by controlling for confounding variables, not inflate them. Study tip: When you see systematic differences in research outcomes that correlate with publication prestige rather than study quality, always consider publication bias first. This is a common issue in meta-analyses and evidence-based medicine questions.

Question 20

A researcher receives funding from a tobacco company to study lung cancer risk factors. The researcher fails to disclose this funding source when publishing results that downplay the role of smoking. Even if the study methodology was sound, what is the primary ethical concern?

  1. The study design was inherently flawed due to industry funding
  2. Readers cannot assess potential conflicts that might influence interpretation (correct answer)
  3. The tobacco company automatically invalidates any scientific findings
  4. Industry-funded research is prohibited in epidemiological studies
  5. The sample size was likely inadequate for detecting smoking effects
Explanation: This question tests your understanding of research ethics, specifically the principle of transparency and disclosure of potential conflicts of interest. When evaluating research integrity, you need to distinguish between methodological quality and ethical transparency requirements. The primary ethical violation here is the failure to disclose funding sources that could create conflicts of interest. Answer B correctly identifies this core issue: readers cannot assess potential conflicts that might influence interpretation. Transparency allows the scientific community and public to evaluate whether financial relationships might have influenced study design, data interpretation, or conclusions. Even with sound methodology, undisclosed conflicts prevent informed evaluation of the research. Let's examine why the other options miss the mark. Answer A incorrectly assumes that industry funding automatically makes study design flawed - this isn't true, as industry-funded research can be methodologically rigorous when properly conducted and disclosed. Answer C takes an extreme position that tobacco company funding automatically invalidates scientific findings - while such funding raises concerns, it doesn't automatically negate all results if methods are sound and conflicts are disclosed. Answer D is factually incorrect, as industry-funded epidemiological research is not prohibited, though it requires careful oversight and disclosure. Remember this key principle for biostatistics ethics questions: the issue often isn't whether research can be conducted under certain circumstances, but whether potential conflicts are properly disclosed. Transparency, not prohibition, is usually the ethical standard. Look for answers that emphasize disclosure and informed evaluation rather than blanket restrictions on research relationships.